Ability to encapsulate, release and ensure effective protection of peptides in the gastrointestinal tract Peptides are rarely orally administrated due to rapid degradation in the gastrointestinal tract and low absorption at the epithelial border. The objective of this study was to encapsulate a model water-soluble peptide in biodegradable and biocompatible solid lipid-based nanoparticles, i.e. Solid […]
Der Beitrag In-vitro evaluation of solid lipid nanoparticles erschien zuerst auf Pharma Excipients.
封装，释放和确保的能力有效保护胃肠道中的肽 肽在胃肠道的快速降解和上皮边界处的低吸收时，很少口服给予。 的目标this study was to encapsulate a model water-soluble peptide in biodegradable and biocompatible solid lipid-based nanoparticles, i.e. Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) in order to protect it from metabolic degradation. Leuprolide (LEU) and a LEU-docusate Hydrophobic Ion Pair (HIP) were encapsulated in SLN and NLC by High Pressure Homogenization. The particles were characterized regarding their Encapsulation Efficiency (EE), size, morphology, peptide release in FaSSIF-V2, and protective effect towards proteases. Nanoparticles of 120 nm with platelet structures were obtained. Formation of HIP led to a significant increase in LEU EE. Particle size was moderately affected by the presence of simulated fluids. Nonetheless, an important burst release was observed upon dispersion in FaSSIF-V2. NLC were able to improve LEU-HIP resistance to enzymatic degradation induced by trypsin but presented no advantages in presence of α-chymotrypsin. SLN provided no protection regarding both proteases. Despite an increased amount of encapsulated peptide in solid lipid-based nanoparticles following HIP formation, the important specific surface area linked to their platelet structures resulted in an important peptide release upon dispersion in FaSSIF-V2 and limited protection towards enzymatic degradation. More on solid lipid nano-particles More on Gattefossé and its excipients Der Beitrag In-vitro evaluation of solid lipid nanoparticles erschien zuerst auf Pharma Excipients.
Der Beitrag 使用绿色造粒技术提高青蒿素立即释放片的溶出度 erschien zuerst auf 医药辅料< / >。< / p >
优化数学模型表明，随着粘结剂浓度的增加，D50增加，粒度分布窄，细粒率最小。较高的粘结剂浓度和叶轮转速会延缓片剂的溶解。PEG 6000和Poloxamer 188片剂崩解和溶出速度均快于Gelucire 50/13片剂，且由于亲水性孔隙形成，湿法制粒片剂溶出速度快于Gelucire 50/13片剂。
采用低水平PEG 6000和Poloxamer 188的熔体造粒技术，与传统的湿造粒技术相比，不仅提高了青蒿素立即释放片的溶出度，而且在高温和潮湿的加速条件下保持了产品的稳定性。 Download full article here: enhancing-dissolution-of-artesunate-from-immediate-release-tablets-using-a-green-granulation-technique.pdf
Der Beitrag Enhancing dissolution of artesunate from immediate release tablets using a green granulation technique erschien zuerst auf Pharma Excipients.
在产品开发中定量选择的意义这些是添加到配方中的添加剂以及药理活性物质。[…]
Der Beitrag 辅料科学的当前发展– erschien zuerst auf 制药辅料.
. .< a> erschien zuerst auf < / div > < h2 >暗示量化各赋形剂的选择产品开发< / h2 > < p >赋形剂的作用,设计不同的剂型不需要任何介绍。这些是添加到配方中的添加剂以及药理活性物质。添加它们的主要目的是增加配方的体积并赋予所需的性能。辅料与原料药一样，需要经过验证和标准化;下一章简要介绍了不同剂型的辅料，包括固体剂型、液体剂型和半固体剂型。考虑到药物先进配方领域的持续发展，我们也涵盖了用于纳米配方的赋形剂。 除此之外，还提供了关于多矿物赋形剂、共加工赋形剂和赋形剂不相容的特别说明，以及赋形剂在制药行业的简要使用历史。 Continue the book chapter on excipients or check excipients basics.
Der Beitrag Current Developments in Excipient Science – Implication of Quantitative Selection of Each Excipient in Product Development erschien zuerst auf Pharma Excipients.